{"id":6411,"date":"2011-07-21T19:18:11","date_gmt":"2011-07-21T13:48:11","guid":{"rendered":"http:\/\/cardiophile.org\/?p=6411"},"modified":"2011-07-21T19:18:11","modified_gmt":"2011-07-21T13:48:11","slug":"assessing-complete-lipid-atherogenic-risk-burden","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/","title":{"rendered":"Assessing complete lipid atherogenic risk burden"},"content":{"rendered":"<p><iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/O-so6dGafGA\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen=\"\"><\/iframe><\/p>\n<h2><span style=\"color: #008000;\">Assessing complete lipid atherogenic risk burden<\/span><\/h2>\n<p>Assessing complete lipid atherogenic risk burden: Even though LDL (low density lipoprotein) cholesterol is currently taken as the important marker of atherogenic risk due to lipids, it is only a partial marker. Complete lipid atherogenic risk burden assessment should take into account all other atherogenic cholesterol particles Lipoprotein (a) [Lp(a)], intermediate-density lipoprotein cholesterol (IDL-C), chylomicron remnants, and VLDL-C (very low density lipoprotein cholesterol).<\/p>\n<p><strong>Apolipoprotein B (apoB) is ideally suited for the direct measurement of all atherogenic lipoproteins <\/strong>together since each atherogenic particle contains 1 apoB100 molecule. Non\u2013HDL-C on the other hand quantifies total atherogenic burden by measuring the total amount of cholesterol in all atherogenic particles taken together. Non\u2013HDL-C = Total cholesterol \u2013 HDL-Cholesterol. It can be obtained in the non-fasting state without affecting the results as the components affected by a meal do not come in the equation. Non\u2013HDL cholesterol is a secondary target of therapy as per the NCEP ATP III (National Cholesterol Education Program Adult Treatment Panel) guidelines. Non\u2013HDL cholesterol has been shown to be an independent predictor of coronary artery disease regardless of triglyceride levels. But LDL cholesterol loses its predictive value with triglyceride levels above 400 mg\/dl [<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8921777\">Frost PH et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation 1996;94:2381-2388<\/a>].<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Complete lipid atherogenic risk burden takes into account all atherogenic cholesterol particles like LDL-C, Lp(a), IDL-C, chylomicron remnants, and VLDL-C.<\/p>\n","protected":false},"author":1,"featured_media":39078,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-6411","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Assessing complete lipid atherogenic risk burden - includes other particles<\/title>\n<meta name=\"description\" content=\"Assessing complete lipid atherogenic risk burden includes all atherogenic cholesterol particles like LDL-C, Lp(a), IDL-C, chylomicron remnants, and VLDL-C.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Assessing complete lipid atherogenic risk burden - includes other particles\" \/>\n<meta property=\"og:description\" content=\"Assessing complete lipid atherogenic risk burden includes all atherogenic cholesterol particles like LDL-C, Lp(a), IDL-C, chylomicron remnants, and VLDL-C.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2011-07-21T13:48:11+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/assessing-complete-lipid-atherogenic-risk-burden\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/assessing-complete-lipid-atherogenic-risk-burden\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Assessing complete lipid atherogenic risk burden\",\"datePublished\":\"2011-07-21T13:48:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/assessing-complete-lipid-atherogenic-risk-burden\\\/\"},\"wordCount\":230,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/assessing-complete-lipid-atherogenic-risk-burden\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/assessing-complete-lipid-atherogenic-risk-burden\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/assessing-complete-lipid-atherogenic-risk-burden\\\/\",\"name\":\"Assessing complete lipid atherogenic risk burden - includes other particles\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/assessing-complete-lipid-atherogenic-risk-burden\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/assessing-complete-lipid-atherogenic-risk-burden\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2011-07-21T13:48:11+00:00\",\"description\":\"Assessing complete lipid atherogenic risk burden includes all atherogenic cholesterol particles like LDL-C, Lp(a), IDL-C, chylomicron remnants, and VLDL-C.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/assessing-complete-lipid-atherogenic-risk-burden\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/assessing-complete-lipid-atherogenic-risk-burden\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/assessing-complete-lipid-atherogenic-risk-burden\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/assessing-complete-lipid-atherogenic-risk-burden\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Assessing complete lipid atherogenic risk burden\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Assessing complete lipid atherogenic risk burden - includes other particles","description":"Assessing complete lipid atherogenic risk burden includes all atherogenic cholesterol particles like LDL-C, Lp(a), IDL-C, chylomicron remnants, and VLDL-C.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/","og_locale":"en_US","og_type":"article","og_title":"Assessing complete lipid atherogenic risk burden - includes other particles","og_description":"Assessing complete lipid atherogenic risk burden includes all atherogenic cholesterol particles like LDL-C, Lp(a), IDL-C, chylomicron remnants, and VLDL-C.","og_url":"https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2011-07-21T13:48:11+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Assessing complete lipid atherogenic risk burden","datePublished":"2011-07-21T13:48:11+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/"},"wordCount":230,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/#primaryimage"},"thumbnailUrl":"","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/","url":"https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/","name":"Assessing complete lipid atherogenic risk burden - includes other particles","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/#primaryimage"},"thumbnailUrl":"","datePublished":"2011-07-21T13:48:11+00:00","description":"Assessing complete lipid atherogenic risk burden includes all atherogenic cholesterol particles like LDL-C, Lp(a), IDL-C, chylomicron remnants, and VLDL-C.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/assessing-complete-lipid-atherogenic-risk-burden\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Assessing complete lipid atherogenic risk burden"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/6411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=6411"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/6411\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=6411"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=6411"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=6411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}